^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Zusduri (mitomycin intravesicular)

    i
    Other names: UGN-102, mitomycin C mixed with TC-3 gel, MMC gel
    Associations

    News

    Trials
    Company:
    UroGen
    Drug class:
    DNA synthesis inhibitor
    Related drugs:
    Associations

    News

    Trials
    5ms
    Novel intravesical delivery systems for nonmuscle invasive bladder cancer. (PubMed, Curr Opin Urol)
    Novel intravesical delivery systems show to enhance drug retention, improve tissue penetration, and potentially reduce adverse events. While traditional chemotherapy or BCG remain the gold-standard adjuvant treatments for NMIBC, these novel approaches offer promising alternatives for selected patients pending on ongoing clinical validation.
    Journal
    |
    FGFR (Fibroblast Growth Factor Receptor)
    |
    paclitaxel • Inlexzo (gemcitabine intravesical system) • Oncofid-P (paclitaxel-hyaluronic acid conjugate) • Zusduri (mitomycin intravesicular) • erdafitinib intravesical delivery system (TAR-210)
    10ms
    UTOPIA: A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer (clinicaltrials.gov)
    P3, N=87, Recruiting, UroGen Pharma Ltd. | Trial completion date: Mar 2026 --> Jul 2026 | Trial primary completion date: Mar 2025 --> Jul 2025
    Trial completion date • Trial primary completion date
    |
    Zusduri (mitomycin intravesicular)
    over1year
    UTOPIA: A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer (clinicaltrials.gov)
    P3, N=87, Recruiting, UroGen Pharma Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Zusduri (mitomycin intravesicular)
    over1year
    UTOPIA: A Phase 3 Single-arm Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer (clinicaltrials.gov)
    P3, N=87, Not yet recruiting, UroGen Pharma Ltd.
    New P3 trial
    |
    Zusduri (mitomycin intravesicular)
    almost2years
    Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle-Invasive Bladder Cancer (NMIBC) (clinicaltrials.gov)
    P3, N=8, Completed, UroGen Pharma Ltd. | Active, not recruiting --> Completed | Phase classification: P3b --> P3 | Trial completion date: May 2023 --> Feb 2023
    Trial completion • Phase classification • Trial completion date
    |
    Zusduri (mitomycin intravesicular)
    2years
    Treatment of Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer with UGN-102 ± Transurethral Resection of Bladder Tumor (TURBT) Compared to TURBT Monotherapy: A Randomized, Controlled, Phase 3 Trial (ATLAS). (PubMed, J Urol)
    Primary, non-surgical chemoablation with UGN-102 for the management of LG IR NMIBC offers a potential therapeutic alternative to immediate TURBT monotherapy and warrants further investigation.
    P3 data • Journal
    |
    Zusduri (mitomycin intravesicular)